Centessa Pharmaceuticals plc
CNTAHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Centessa Pharmaceuticals plc focuses on Biotechnology services and products. Centessa Pharmaceuticals plc, together with its subsidiaries, discovers, develops, and delivers orexin-based neuroscience therapeutics in the United Kingdom and the United States. With a market capitalization of $6.27B, it sits in mid-cap territory. The company develops ORX750, an orexin receptor 2 agonist, which is in Phase IIa clinical trial for the treatment of central disorders of hypersomnolence, including narcolepsy type 1 and 2, as well as idiopathic hypersomnia.
Market Cap
$6.27B
Beta
1.12
P/E (TTM)
—
P/E (Fwd)
-22.75
EPS (TTM)
$-1.78
EPS (Fwd)
$-1.78
ROE
-57.4%
ROA
-27.4%
Cash
$276.6M
Total Debt
$118.6M
Free CF
-$128.7M
52W Change
210.6%
Annual Financials
Cash vs Debt
Centessa Pharmaceuticals plc holds $276.6M in cash against $118.6M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. The company is burning cash, with free cash flow at -$128.7M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -57.4% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
With cash comfortably exceeding debt, CNTA has financial flexibility that may help navigate uncertain periods. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. No single metric tells the full story. Reviewing CNTA's risk profile alongside its fundamentals and technical indicators provides a more complete picture.